MK-1293

DRUG3 trials

Sponsors

Merck Sharp & Dohme LLC

Conditions

Type 1 Diabetes MellitusType 2 Diabetes Mellitus

Phase 1

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MK-1293 Compared With a Basal Insulin in Participants With Type 1 Diabetes (MK-1293-005)

CompletedNCT02059174

Merck Sharp & Dohme LLCType 1 Diabetes Mellitus

Start: 2014-02-10End: 2015-04-27Updated: 2018-09-05

Phase 3

The Safety and Efficacy of MK-1293 Versus Lantus™ in Participants With Type 2 Diabetes Mellitus (MK-1293-006)

CompletedNCT02059187

Merck Sharp & Dohme LLCType 2 Diabetes Mellitus

Start: 2014-02-11End: 2015-03-11Updated: 2018-09-06

A Study of the Safety and Efficacy of MK-1293 Compared to Lantus™ in Participants With Type 1 Diabetes Mellitus (T1DM) (MK-1293-003)

CompletedNCT02059161

Merck Sharp & Dohme LLCType 1 Diabetes Mellitus

Start: 2013-10-17End: 2015-11-12Updated: 2018-09-05

Related Papers

Efficacy and safety of MK-1293 insulin glargine compared with originator insulin glargine (Lantus) in type 2 diabetes: A randomized, open-label clinical trial.

2018-06-109 citations

Efficacy and safety of MK‐1293 insulin glargine compared with originator insulin glargine (Lantus) in type 1 diabetes: A randomized, open‐label clinical trial

Diabetes Obesity and Metabolism2018-05-168 citations

Single‐dose euglycaemic clamp studies demonstrating pharmacokinetic and pharmacodynamic similarity between <scp>MK</scp> ‐1293 insulin glargine and originator insulin glargine ( <scp>L</scp> antus) in subjects with type 1 diabetes and healthy subjects

Diabetes Obesity and Metabolism2017-08-1720 citations